- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.01. | Citius Oncology weighs strategic options on road to launching newly-approved lymphoma med | - | FiercePharma | ||
| 06.01. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | - | SEC Filings | ||
| 27.12.24 | Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update | 299 | PR Newswire | CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company... ► Artikel lesen | |
| 27.12.24 | CITIUS ONCOLOGY, INC. - 8-K, Current Report | - | SEC Filings | ||
| 27.12.24 | CITIUS ONCOLOGY, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 22.11.24 | CTOR stock touches 52-week low at $0.9 amid market challenges | 2 | Investing.com | ||
| 22.11.24 | CTOR-Aktie erreicht 52-Wochen-Tief bei 0,9 US-Dollar | 4 | Investing.com Deutsch | ||
| 11.11.24 | Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients ... | 136 | PR Newswire | Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled27%... ► Artikel lesen | |
| CITIUS ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 09.10.24 | CTOR-Aktie erreicht 52-Wochen-Tief bei 1,02 US-Dollar | 3 | Investing.com Deutsch | ||
| 01.10.24 | CTOR stock touches 52-week low at $1.29 amid market challenges | 1 | Investing.com | ||
| 13.09.24 | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.09.24 | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.08.24 | CTOR stock touches 52-week low at $1.67 amid market challenges | 1 | Investing.com | ||
| 16.08.24 | Citius Oncology Inc. completes strategic acquisition | 2 | Investing.com | ||
| 16.08.24 | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.08.24 | CTOR stock touches 52-week low at $3.20 amid market fluctuations | 4 | Investing.com | ||
| 13.08.24 | NSE - CITIUS ONCOLOGY, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 4 | SEC Filings | ||
| 12.08.24 | Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. | 177 | PR Newswire | LYMPHIR for the treatment of cutaneous T-cell lymphoma approved by the FDA
Citius Pharmaceuticals, Inc. holds approximately 90% of publicly traded Citius Oncology, Inc.
Shares of Citius Oncology, Inc.... ► Artikel lesen | |
| 09.08.24 | CITIUS ONCOLOGY, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.08.24 | TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination with Citius Oncology, and Provides Market Update | 721 | GlobeNewswire (Europe) | New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- On August 7, 2024, TenX Keane Acquisition (Nasdaq: TENKU, TENK, TENKR) ("TenX"), a publicly traded special purpose acquisition company, was notified by... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 1,840 | -0,76 % | Fast 200 % Kurspotenzial! Nel ASA, Evotec, BioNTech, Medigene Aktien! | Die Aktie von Medigene hat mit dem Turnaround begonnen. Neben positiven Patent-News aus Japan für das Krebs-Testis-Antigen MAGE-A4 treibt eine Kaufempfehlung das Wertpapier. So sehen Analysten mehr... ► Artikel lesen | |
| BB BIOTECH | 40,500 | +0,87 % | BB Biotech schafft 2024 Rückkehr in Gewinnzone | Schaffhausen - Der Beteiligungsgesellschaft BB Biotech ist nach drei verlustreichen Jahren 2024 die Rückkehr in die Gewinnzone geglückt. Den Aktionären will die Gesellschaft eine tiefere Dividende zahlen.... ► Artikel lesen | |
| QIAGEN | 43,595 | -0,34 % | Qiagen schüttet clever aus | Bei Qiagen profitieren Anleger nicht nur von verbesserten fundamentalen Aussichten: Das Unternehmen schüttet erneut Kapital über einen Reverse Stock Split aus - insgesamt 300 Mio. US-Dollar. Die Venloer... ► Artikel lesen | |
| NOVAVAX | 8,789 | +0,09 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| STRYKER | 377,90 | +0,61 % | Strong Segmental Performance to Drive Stryker's Q4 Earnings? | ||
| ILLUMINA | 130,58 | +0,62 % | Inside the New Illumina MiSeq i100 Series: The Making of the Software | What's it like to build the software in a brand-new sequencer? Illumina's Aneesh Natarajan takes us on the journeyOriginally published on Illumina News Center NORTHAMPTON, MA / ACCESS Newswire / January... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 39,800 | -3,86 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results | -CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized... ► Artikel lesen | |
| AAP IMPLANTATE | 1,860 | -1,06 % | EQS-News: aap Implantate AG: Deutliche Fortschritte in allen operativen Bereichen; stabiles viertes Quartal führt zu 12.2 Mio. EUR Jahres-Umsatz (+6%) | EQS-News: aap Implantate AG
/ Schlagwort(e): Vertriebsergebnis
Deutliche Fortschritte in allen operativen Bereichen; stabiles viertes Quartal führt zu 12.2 Mio. EUR Jahres-Umsatz... ► Artikel lesen | |
| OCUGEN | 0,712 | -4,05 % | Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 | OCU500 will be administered via inhalation and as a nasal sprayCOVID-19 remains a substantial public health threat in the U.S. and around the worldPhase 1 clinical trial is anticipated to start in... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 1,119 | +0,83 % | Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts | ||
| INTELLIA THERAPEUTICS | 9,830 | -6,02 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema | CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| SCORPIUS | 0,274 | 0,00 % | XFRA 1HB0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSCORP.HLDGS.NEW... ► Artikel lesen | |
| EDITAS MEDICINE | 1,330 | +1,49 % | Editas Medicine, Inc.: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities | Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,190 | -1,51 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) | -ORLADEYO net revenue expected to be between $515-$535 million in 2025- -Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025- -Company achieved operating profit in... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,660 | +19,13 % | Defence Therapeutics Inc.: Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025 | Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radiopharmaceuticals... ► Artikel lesen |
Das Unternehmen CITIUS ONCOLOGY INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,300 Euro und damit +4,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CITIUS ONCOLOGY INC finden Sie auf Wallstreet Online.
